12 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
TTWO Take-Two Interactive Software, Inc. $131.48 $14.97B N/A
Article Searches
Takeda down 2% on underwhelming TAK-788 data https://seekingalpha.com/news/3464620-takeda-2-percent-underwhelming-takminus-788-data?source=feed_news_all May 16, 2019 - Investors appear unmoved with interim data from an open-label Phase 1/2 clinical trial evaluating Takeda's (TAK -2.4%) oral TKI inhibitor TAK-788 in non-small cell lung cancer (NSCLC) patients
What's in the Cards for Sunesis (SNSS) This Earnings Season? http://www.zacks.com/stock/news/406478/whats-in-the-cards-for-sunesis-snss-this-earnings-season?cid=CS-ZC-FT-406478 May 01, 2019 - Sunesis Pharmaceuticals' (SNSS) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, vecabrutinib.
Seattle Genetics (SGEN) Q1 Loss Narrows, Revenues Top Mark http://www.zacks.com/stock/news/404524/seattle-genetics-sgen-q1-loss-narrows-revenues-top-mark?cid=CS-ZC-FT-404524 Apr 26, 2019 - Seattle Genetics (SGEN) betters loss estimates in Q1 and also rides high on revenue beat.
Kamada to Begin Phase III Study for Inhaled AAT Product in 2H http://www.zacks.com/stock/news/384736/kamada-to-begin-phase-iii-study-for-inhaled-aat-product-in-2h?cid=CS-ZC-FT-384736 Apr 17, 2019 - Kamada (KMDA) wins the FDA acceptance for the path forward regarding its inhaled Alpha-1-Antitrypsin product, currently under development for treating Alpha-1 Antitrypsin Deficiency.
Company News For Mar 5, 2019 http://www.zacks.com/stock/news/357738/company-news-for-mar-5-2019?cid=CS-ZC--357738 Mar 05, 2019 - Companies in the news are; PLCE, BIIB, NITE, ASND and TAK
Ironwood to Get New CEO, Current CEO to Head Latest Spinoff http://www.zacks.com/stock/news/346023/ironwood-to-get-new-ceo-current-ceo-to-head-latest-spinoff?cid=CS-ZC-FT-346023 Jan 07, 2019 - Ironwood Pharma (IRWD) appoints AstraZeneca executive, Mark Mellon, as its new chief executive officer. Peter Hecht, the current CEO, will lead the new spinoff company focusing on rare disease.
Takeda and Ovid Therapeutics expand clinical program for TAK-935/OV935 https://seekingalpha.com/news/3370995-takeda-ovid-therapeutics-expand-clinical-program-takminus-935-ov935?source=feed_news_all Jul 18, 2018 - Takeda Pharmaceutical (OTCPK:TKPYY) and Ovid Therapeutics (NASDAQ:OVID) will expand their TAK-935/OV935 clinical development program to include three clinical trials:Phase 2 ARCADE: A multicenter
Q&A: Georgia blues icon Tinsley Ellis taks Allman Brothers, new album, Alligator Records http://feeds.bizjournals.com/~r/industry_18/~3/f3gtOQgQ22s/q-a-georgia-blues-icon-tinsley-ellis-taks-allman.html Jan 10, 2018 - On Jan. 9, Atlanta Business Chronicle's Phil W. Hudson spoke with the Georgia-based blues-rock guitarist, singer-songwriter Tinsley Ellis. The Atlanta native is a living legend in the blues community. He has performed in all 50 states, plus Canada, Western and Eastern Europe, Australia and South America. He has shared the stage with countless other iconic musicians, including The Allman Brothers (interview with Gregg Allman here and Butch Trucks here), Stevie Ray Vaughan, Widespread Panic (interview…
Fuyao chairman talks ousted execs, 'culture clash' in weekend piece http://feeds.bizjournals.com/~r/industry_8/~3/jHejZx40Yk8/fuyao-chairman-talks-ousted-execs-culture-clash-in.html Jun 12, 2017 - Fuyao Chairman Cho Tak Wong spoke on the current state of Fuyao Glass America Inc. in an article published over the weekend. In a weekend feature, New York Times examined the 'culture clash' at Fuyao Glass America amid a lawsuit, safety complaints and push for unionization in the Moraine auto glass plant. In it, the paper talked to Cho, also called Cao Dewang, as well as a number of workers and analysts on the state of the Chinese company's biggest North American operations, Fuyao Glass America…
Chinese glass plant in Ohio dealing with 'major culture clash,' report finds http://feeds.bizjournals.com/~r/industry_8/~3/0rEsbkpxY88/chinese-glass-plant-in-ohio-dealing-with.html Jun 12, 2017 - Fuyao Chairman Cho Tak Wong spoke on the current state of Fuyao Glass America Inc. in an article published over the weekend. The New York Times examined the 'major culture clash' at Fuyao Glass America amid a lawsuit, safety complaints and push for unionization in the Moraine auto glass plant outside Dayton. In it, the paper talked to Cho, also called Cao Dewang, as well as a number of workers and analysts on the state of the Chinese company's biggest North American operations, Fuyao Glass America…

Pages: 12

Page 1